Q3 FY2026 · ended Sep 30, 2026 · Revenue $0 · Filed Nov 5, 2026
Tenax Therapeutics, Inc. (TENX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $16.7 million.
Revenue
$0
Net income
$-16.70M
-5.7% vs year-ago quarter
Operating cash flow
$-12.48M
-36.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.31
+22.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
45.54M
+629.3% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TENX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chapel Hill, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 34956
- Former names
- OXYGEN BIOTHERAPEUTICS, INC. (until Sep 15, 2014); SYNTHETIC BLOOD INTERNATIONAL INC (until Jun 30, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$17.7M | -$18.8M | -$16.6M | -$16.4M | -$16.8M |
| Net income | -$16.7M | -$17.8M | -$15.7M | -$15.5M | -$15.8M |
| Diluted EPS | -$0.31 | -$0.35 | -$0.35 | -$0.38 | -$0.40 |
| Operating cash flow | -$12.5M | -$14.2M | -$9.3M | -$13.4M | -$9.2M |
| Total assets | $117.0M | $121.7M | $123.2M | $104.2M | $102.8M |
| Total liabilities | $8.4M | $8.1M | $8.5M | $7.2M | $6.6M |
| Stockholders' equity | $108.7M | $113.6M | $114.7M | $97.1M | $96.2M |
| Cash and investments | $113.7M | $118.0M | $118.8M | $97.6M | $99.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
All 995 Tenax Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.